Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tertinat in Atherosclerotic Patients After Coronary Revascularization
NCT06590012Phase 2Active, not recruiting
- Sponsor
- Institute for Atherosclerosis Research
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- Nutraceutical
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis comparing Tertinat with Placebo (2 arms). Primary endpoints: Rate of fatal cardiovascular events at 24 months, Rate of non-fatal cardiovascular events at 24 months and 1 more. Started Aug 2024; status: active, not recruiting.
02
Drugs
Tertinat
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT06590012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590012.